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Abstract 
The aim of this study was to measure the levels of circulating BDNF and the frequency of   
BDNF-producing T cells after acute ischaemic stroke. Serum BDNF levels were measured by 
ELISA. Flow cytometry was used to enumerate peripheral blood leukocytes that were labelled 
with antibodies against markers of T cells, T regulatory cells (Tregs), and intracellular BDNF.  
There was a slight increase in serum BDNF levels after stroke.  There was no overall difference 
between stroke patients and controls in the frequency of CD4
+
 and CD8
+
 BDNF
+
 cells, 
although a subgroup of stroke patients showed high frequencies of these cells. However, there 
was an increase in the percentage of BDNF
+
 Treg cells in the CD4
+
 population in stroke 
patients compared to controls. Patients with high percentages of CD4
+
 BDNF
+
 Treg cells had a 
better outcome at 6 months than those with lower levels. These groups did not differ in age, 
gender or initial stroke severity. Enhancement of BDNF production after stroke could be a 
useful means of improving neuroprotection and recovery after stroke.   
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1. Introduction  
Ischemic stroke is caused by interruption of supply of blood to a part of the brain, creating an 
environment of hypoxia and glucose deprivation that leads to neuronal death and neurological 
deficits (Moustafa and Baron 2008). After stroke there is local inflammation at the site of 
injury (Gelderblom et al. 2009), which can be  harmful in the early stages since activation of 
microglial cells and local inflammatory responses exacerbate injury to the brain (Jin et al. 
2010).  There is also systemic immune activation after stroke (Yan et al. 2009). We have 
previously reported that stroke subjects have increased  levels of circulating anti-inflammatory 
cytokines (Yan et al. 2012a) and  upregulation of CD4
+
CD25
hi 
Foxp3
+
 T regulatory cells 
(Tregs) after stroke (Yan et al. 2012b). The increase in anti-inflammatory cytokines and the 
increased frequency of circulating Tregs  could serve to reduce harmful inflammation. 
However, the overall effects of the systemic activation of the immune system after stroke are 
complex and may include beneficial effects (McCombe and Read 2008;Yilmaz et al. 2006).  
 
Beneficial effects of the immune response after stroke could be mediated by protective 
immunity, which plays a role in recovery from injury and which is mediated through Tregs. 
Tregs have the functions of negative regulation of immune responses, self-tolerance and 
control of damage at the site of inflammation (Tang and Bluestone 2008;Wan 2010). In 
experimental stroke, the absence of Tregs in mice caused elevated expression of pro-
inflammatory cytokines,  indicating the role of Tregs in protection in acute ischemic stroke 
(Liesz et al. 2009). Adoptive transfer of Treg cells led to reduction of volume of ischaemia in 
experimental stroke (Brea et al. 2014).  However, the role of Treg cells in recovery from stroke 
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may be different at different time points after stroke (Chen et al. 2013;Kleinschnitz et al. 
2013;Xu et al. 2013).    
 
Neurotrophins are molecules that promote the growth and survival of neurons   (Huang and 
Reichardt 2001).  One important neurotrophin is brain derived neurotrophic factor (BDNF) 
which improves neuronal survival and prevents neuronal death by activating intracellular 
protein kinases B and mitogen-activated protein kinases (MAPK/ERK) (Schabitz et al. 2000). 
Administration of BDNF in regional brain ischemia caused both a reduction in stroke volume 
and an improvement in functional outcome (Zhang and Pardridge 2006).  There is only one 
study of circulating levels of BDNF after stroke, which found no increase in BDNF levels in 10 
stroke subjects sampled at admission and daily for the following four days (Di Lazzaro et al. 
2007).  
 
However, even if circulating levels are unchanged, another possibility is that Tregs could  
deliver neurotrophins, such as BDNF, to the site of injury, and these  could assist in recovery 
(Greenberg et al. 2009). It is known that activated human T cells, B cells and monocytes 
secrete BDNF in vitro (Kerschensteiner et al. 1999) and can be shown to produce BDNF by 
intracellular labelling with flow cytometry  (Ziemssen et al. 2002). To investigate the 
possibility that Tregs produce BDNF after human stroke, we have measured circulating BDNF 
levels and production of BDNF by T cells after stroke. We also investigated whether the levels 
of BDNF
+
 Tregs correlated with the clinical features after stroke. 
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2. Materials and Methods 
Patients and controls 
The study protocol was reviewed and approved by the Human Research Ethics Committee of 
the Royal Brisbane and Women's Hospital, the Wesley Hospital and the Medical Research 
Ethics Committee of the University of Queensland, Australia. All participants provided 
informed consent prior to study participation. The ischemic stroke patients were recruited from 
the Department of Neurology in the Royal Brisbane and Women’s Hospital and the Wesley 
Hospital, Brisbane, Australia. Ischemic stroke was diagnosed on the clinical history, presence 
of focal neurological signs and symptoms and by Magnetic Resonance Imaging (MRI) or CT 
scans. Patients with subarachnoid haemorrhage, extradural or subdural haemorrhage, transient 
ischemic attack (TIA, defined using standard criteria) or a neurological deficit caused by 
trauma or neoplasm were excluded. We documented the clinical details, such as the presence of 
hypertension, through self-report by the patients or by questioning their relatives. Healthy 
controls were volunteers with no history of acute or chronic illness.  
 
Table 1 shows the details of the subjects used for measurements of BDNF levels and for the 
flow cytometry study. The day of onset of stroke was taken as Day 0. For the flow cytometry 
study, blood was collected from stroke subjects up to three weeks after stroke. Six of the 
subjects were treated with thrombolysis in the emergency department on day 0. These subjects 
were enrolled in the present study on the next day, so that the initial clinical assessment was 
done the day after thrombolysis.   
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Classification of stroke and measurement of stroke severity  
Patients were classified according to the Oxfordshire Stroke Classification (OSSC) (Bamford et 
al. 1991) into total anterior circulation infarcts (TACI), partial anterior circulation infarct 
(PACI), posterior circulation infarct (POCI) and lacunar infarcts (LACI). Stroke severity was 
assessed with the National Institutes of Health Stroke Scale (NIHSS) at day 1.Dependency was 
measured at baseline and 6 months using the modified Barthel index (mBI) (Mahoney and 
Barthel 1965;Sulter et al. 1999).  
 
Isolation of PBMC and cell culture  
Venous blood samples were collected within the first 3 weeks following stroke. For some 
patients, samples were collected at several times during this period; in those cases, only data 
from one time-point is reported in the current study. . Blood was collected on one occasion 
from controls. Serum was used for measuring BDNF levels. Peripheral blood mononuclear 
cells (PBMCs) were separated by density centrifugation, as we have previously described (Yan 
et al. 2009) and cryopreserved. Cryopreserved PBMC samples were thawed and cultured in 
RPMI1640 supplemented with 10% FCS for 24 h before use to allow cells to rest and re-
express cell surface molecules. We have previously reported results of Treg cells in freshly 
collected cells from subjects with stroke (Yan et al. 2012b), and six of those subjects were 
included in the present study.  
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Antibody labeling and flow cytometry   
Prior to analysis on a Beckman Coulter Gallios flow cytometer with seven color acquisition, 
cells were stained with Aqua Live/Dead cell exclusion dye (Invitrogen) and surface stained 
with the following fluorochrome-conjugated antibodies: anti-CD25 fluorescein isothiocyanate 
(Becton   Dickinson), anti-CD8 PerCP-Cy 5.5 (Becton Dickinson), anti-CD127 phycoerythrin-
Cy7 (eBioscience) and anti-CD4 V450 (Becton   Dickinson). Cells were fixed and 
permeabilized using a cytofix/cytoperm kit according to the manufacturer’s instructions 
(Becton Dickinson), before intracellular staining with Anti-FoxP3 phycoerythrin (eBioscience) 
and anti-BDNF allophycocyanin (Neuromics) conjugated antibodies. 
 
Single labelled tubes for each antibody, isotype-matched control antibodies, fluorescence-
minus-one controls, dead cell exclusion and doublet discrimination were used to ensure 
accurate positive cut-off values and compensation matrices and to validate cell phenotype 
detection sensitivity and resolution.  
 
Figure 1 shows the gating strategy used to identify BDNF+ve regulatory T cells. Flow 
cytometry data was analyzed using Kaluza 1.2 software (Beckman Coulter).   
 
BDNF levels  
BDNF concentrations in the serum were measured using BDNF Emax ImmunoAssay System 
sandwich ELISA kits (Promega, WI, USA) according to the manufacturer’s instructions. 
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Briefly, 96-well flat-bottom plates (Corning Costar Corp., Cambridge, MA) were coated 
overnight at 4C with anti-BDNF mAb. Next day, the plates were washed, blocked and then 
100 l of a 1:100 dilution of serum per well was added. Each sample was tested in triplicate. 
Serial dilutions of the BDNF standards were also tested on each plate,  to allow the 
concentration of the BDNF in the serum samples to be determined. The plates were incubated 
for two hours at room temperature and then were washed and incubated with anti-human 
BDNF polyclonal antibody for two hours at room temperature. After washing, plates were then 
incubated with anti-IgY conjugated horseradish-peroxidase for one hour at room temperature. 
Finally, TMB (3,3,5,5-tetramethylbenzidine) substrate solution was added for 10 min, the 
reaction was stopped by addition of 1N HCl, and plates were read at 450 nm. The 
concentration of the BDNF was determined from the standard calibration curve. This ELISA 
kit detects a minimum of 15.6 pg/ml of BDNF, with less than 3% cross reactivity with other 
related neurotrophic factors at 100 ng/ml.  
 
Statistical analysis   
Statistical analyses were performed using GraphPad Prism, version 5.03 (GraphPad Software 
Inc., San Diego, California, USA). The D’Agostino and Pearson omnibus normality test was 
used to determine whether distributions were normal. Depending on the distribution of the data, 
two-tailed t-tests or the Mann-Whitney U test were used to compare the healthy control and 
stroke populations. A P value of <0.05 was considered to be significant.   
3. Results  
3.1 Serum BDNF levels in stroke subjects and controls 
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The level of BDNF was measured in serum of 75 stoke patients and 56 healthy controls.  The 
median serum BDNF concentration in the stroke subjects was slightly greater than that in the 
healthy controls (p=0.04). These results are shown in the left panel of Figure 2. The results for 
BDNF levels according to the time after stroke (Day 1, Week 1, Week 3) are also shown in 
Figure 2. The levels in these subgroups did not differ significantly from that of controls. 
 
3.2  Frequency of BDNF-producing T cells after stroke 
In 39 patients with stroke, the overall frequency of CD4
+
BDNF
+
 cells and CD8
+
 BDNF
+
 cells 
was not different from that of 15 healthy controls.   However, a subgroup of 5 stroke subjects 
had very high levels of both of these groups of cells of CD4+ BDNF+ T cells (Figure 3). The 
CD4+ BDNF+ T cell percentages according to the time after stroke are also shown in Figure 3 
 
We then examined the percentage of CD4
+
CD25
hi
Foxp3
+
CD127
low/- 
BDNF
+
 cells in the CD4
+
 
population (Figure 4) The percentage of such BDNF
+
 Tregs in the CD4
+
 population was higher 
in stroke patients than in controls (P<0.01). Again, the 5 patients who had the high levels of 
CD4
+
 and CD8
+
 BDNF
+
 T cells also had the highest levels of BDNF
+
 Tregs. The percentage of 
BDNF
+
 Tregs in the CD4
+
 population at Day 1, Week 1 and Week 3 after stroke is also shown 
in Figure 4.  
 
We also calculated the percentage of BDNF+ Tregs in the Treg population. This is shown in Figure 5. 
This did not vary between controls and stroke subjects, indicating that the increase in BDNF+ Tregs is 
part of the general increase in Treg cells. 
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3.3 Outcome at 6 months in subjects with high and low levels of CD4
+
BDNF
+
 Treg cells 
The subgroup of stroke patients who had percentages of BDNF
+
 Tregs in their blood that 
exceeded the 90% percentile of the healthy control group were classified as “hi BDNF”. There 
was no difference between the two groups in the severity of the stroke as measured by NIHSS 
(dat not shown), or in age or gender. The hi BDNF group had slightly more dependency at 
onset, as measured by the mBI (Figure 5). However, their outcome following stroke, as 
measured by the mBI at 6 months, was significantly better than that of patients who had lower 
levels of BDNF
+
 Tregs in their blood (“low BDNF” group; * P<0.05 using a 2-tailed Mann-
Whitney U test) (Figure 6). Two patients in the low BDNF group had died before 6 months, 
and are given a mBI of 0 in the figure.  Four other patients in the low BDNF group were not 
able to be contacted at the 6 month timepoint. 
 
 
4. Discussion 
In the present study we investigated the levels of circulating BDNF, levels of peripheral 
BDNF
+
  Treg, and whether there was any association between BDNF
+
 Treg levels and the 
outcome after stroke. There was a slight increase in circulating BDNF levels after stroke, a 
higher percentage of BDNF+ Tregs in the blood following stroke, and the subjects with high 
levels of BDNF
+
 Tregs had a better outcome at 6 months.  The levels of  Treg cells are still 
low, and the increase in BDNF+ Treg cells is in proportion to the increase in Treg cells. 
However, these cells could play a role in recovery from stroke, because we also found that 
individuals with high levels had a better outcome at 6 months.  
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The role of nerve growth factors in recovery after stroke is a topic of interest, and 
administration of BDNF, which is thought to play a  role in neuronal survival, differentiation, 
and neuroplasticity (Binder and Scharfman 2004;Greenberg et al. 2009), has been reported to 
improve outcome in experimental stroke in rats (Zhang and Pardridge 2006). In the current 
study, we found only a slight increase in circulating BDNF levels after stroke, and a previous 
small study found no increase in BDNF levels after stroke (Di Lazzaro et al. 2007). This would 
suggest that increases in circulating BDNF are unlikely to contribute to recovery after stroke.  
 
The role of Tregs in recovery from stroke has been of great interest, because of the possibility 
that these cells could be beneficial, although there have been different opinions about this topic 
(Liesz et al. 2009;Chen et al. 2013). But results from experimental animal models of stroke 
suggest that Tregs can traffic to the site of the stroke. Our finding of the increased numbers of 
BDNF-producingTreg cells after stroke suggests the possibility that Treg cells may be able to 
supply BDNF to the site of injury to provide neuroprotection after the stroke.  The stroke 
subjects showed variability in the levels of BDNF
+
 Tregs after stroke. However, there was no 
difference between the hi BDNF group and the lo BDNF group in age, gender or severity of 
stroke. Therefore, the levels of these cells could be related to individual genetic factors, 
includingCD28 expression (Gogishvili et al. 2013) and a number of other genes (Ferraro et al. 
2014). In those individuals with high levels of BDNF
+
 Treg cells after stroke, the clinical 
outcome was better at 6 months. This suggests that high levels of these cells are beneficial.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
The limitations of our study are that the sample size is relatively small, and that we do not have 
measurements of stroke volume for correlation with our results. We had complete data for the 
mBI as a measure of outcome, but did not have complete data for the modified Rankin scale, 
which is another common measure of stroke outcome (Sulter et al. 1999). Despite this, or data 
showed a significant effect of hi BDNF Treg cells on outcome.  
 
We consider that the ability to produce high levels of BDNF Treg cells is most likely to be due 
to individual factors. For those subjects who do not produce high levels of these cells, we 
suggest that enhancing this response could beneficial, possibly as a means of delivering BDNF 
to the site of injury. Other studies that support the role of BDNF in recovery after stroke 
showed that BDNF-expressing neural stem cells were beneficial (Chang et al. 2013), as were 
mesenchymal stem cells (Jeong et al. 2014). Methods such as the use of histone deacetylase 
inhibitors (Kim et al. 2009) or a CD28 superagonist, as have already been shown to be 
beneficial in experimental stroke (Na et al. 2015), are possible strategies to increase the number 
of Treg cells. Given the lack of therapies to improve outcome after stroke, further studies of the 
role of BDNF-producing T reg cells would be useful. 
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 Ischemic stroke patients Healthy controls 
 Serum ELISA FACS analysis Serum ELISA FACS analysis 
Number, n  
Total 
Female 
Male 
75 
31 
44 
39 
17 
22 
56 
27 
29 
15 
9 
6 
Median age (range) 69 (27-89) 71 (32-88) 43 (20-95) 62 (27-78) 
Hypertension (%) 70.7% 79.5% 19.6% 26.7% 
Median NIHSS 
(IQR)* 3.5 (0-24) 3.0 (1-8) N/A N/A 
Median mRS (IQR)* 3.0 (0-6) 3.0 (2-4) N/A N/A   
OSCC, n (%)* 
LACI 
PACI 
POCI 
TACI 
watershed 
21.3% 
41.3% 
21.3% 
12.0% 
1.3% 
17.9% 
28.2% 
35.9% 
15.4% 
2.6% 
N/A 
 
 
 
 
N/A 
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*data not available for 1 patient in serum group 
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Figure legends: 
 
Figure 1. Flow cytometric gating strategy.  
Lymphocytes were identified on the basis of forward and side scatter (A). Viable lymphocytes 
were selected on the basis of Aqua viability dye exclusion (B), and, of these cells, CD4+ 
CD25+ T cells were selected (C). The portion of these cells that were negative for CD127 and 
positive for FoxP3 expression (D) were assessed for BDNF expression (E). 
 
Figure 2. BDNF levels in serum 
The left panel shows the BDNF levels in all samples taken from controls and stroke subjects. 
BDNF levels were slightly elevated in the serum of subjects with stroke (n=75) compared to 
healthy controls (n=56).  The error bars shows the median and interquartile range.. P=0.03 
using two-tailed Mann-Whitney U test. The right panel shows the levels of BDNF at day 1, 
week 1 and week 3 after stroke. When these subgroups are compared with the control group 
there was no significant difference.  
 
 
 
Figure 3.  Percentage of BDNF+ cells in CD4+ population 
The left panel shows the percentages of BDNF
+
 cells in the CD4
+
 population. This did not 
differ significantly between subjects with stroke (n=39) and healthy controls (n=15), although 
5 stroke patients had highly elevated levels of BDNF
+
 producing cells in both the CD4
+
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
populations. Error bars show the median and interquartile range. The right panel shows the 
values for the stroke subjects at day 1,  
 
 
Figure 4.  Percentages of CD4
+
CD25
hi
Foxp3
+
CD127
low/- 
BDNF
+
 cells in the CD4
+
 
population 
Percentages of BDNF
+
 Tregs in the CD4
+
 population were significantly higher in stroke 
patients (n=39) than in controls (n=15) (P<0.01 by two tailed Mann-Whitney U test). Again, 
the 5 patients who had the high levels of CD4
+
 and CD8
+
 BDNF
+
 T cells also had the highest 
levels of BDNF
+
 Tregs. Error bars show the median and interquartile range. 
 
Figure 5  Percentage of BDNF+ Tregs in the Treg population 
This shows the percentage of BDNF Tregs in the Treg population, in healthy controls and 
subjects at Day 1, Week 1 and Week 7 after stroke. There was no difference between the 
groups, indicating that the increase in BDNF+ Tregs was in proportion to the overall in crease 
in Tregs in stroke. Error bars show the median and interquartile range. 
 
 
 
Figure 6.  Effects of levels of Cd4+BDNF+ T reg cells on outcome at 6 months. 
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6 month follow-up of patients with high and low levels of CD4
+
BDNF
+
Treg cells. The 
subgroup of stroke patients who had percentages of BDNF
+
 Tregs in their blood that exceeded 
the 90
th
 percentile of the healthy control group were classified as “hi BDNF” and the other 
patients were classified as “lo BDNF”.  At baseline there was no significant difference between 
the Barthel index score (mBI) in the 2 groups. Their outcome following stroke, as measured by 
the mBI at 6 months, was significantly better than that of patients who had lower levels of 
BDNF
+
 Tregs in their blood (“low BDNF” group;  P<0.05 using a 2-tailed Mann-Whitney U 
test). Two patients in the low BDNF group had died before 6 months, and are given a mBI of 0 
in the figure.  Four other patients in the low BDNF group were not able to be contacted at the 6 
month timepoint. 
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Fig. 1
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Fig. 2
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Fig. 3
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Fig. 4
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Fig. 5
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Highlights 
 
• We measured Treg cells and BDNF positive Treg cells in subjects with  acute ischaemic stroke 
• The frequency of Treg and BDNF positive Treg was increased in subjects after stroke 
• Patients with high levels of BDNF positive Treg cells had a better outcome than other patients 
• There was a slight increase in circulating levels of BDNF 
• We propose that PDNF positive Treg cells could deliver BDNF to the site of stroke and could be 
beneficial 
